Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 65 Return-on-Tangible-Asset is -24.22% as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 65/100 and a GF Value™ of €2.10 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 70.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pangaea Oncology's annualizedNet Income for the quarter that ended in Dec. 2025 was €-3.81 Mil. Pangaea Oncology's average total tangible assets for the quarter that ended in Dec. 2025 was €15.72 Mil. Therefore, Pangaea Oncology's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -24.22%.
The historical rank and industry rank for Pangaea Oncology's Return-on-Tangible-Asset or its related term are showing as below:
XMAD:PANG'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -48.88 Med: -17.63 Max: -5.68
Current: -22.27
During the past 13 years, Pangaea Oncology's highest Return-on-Tangible-Asset was -5.68%. The lowest was -48.88%. And the median was -17.63%.
XMAD:PANG's Return-on-Tangible-Asset is ranked worse than 70.42% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs XMAD:PANG: -22.27
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pangaea Oncology Return-on-Tangible-Asset Related Terms
Pangaea Oncology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -24.22% mean?
Pangaea Oncology (XMAD:PANG) has a Return-on-Tangible-Asset of -24.22% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #150 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 70.4%.
Is Pangaea Oncology's Return-on-Tangible-Asset too high?
Pangaea Oncology's current Return-on-Tangible-Asset is -24.22%. Based on the distribution chart, Pangaea Oncology ranks #150 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #150 out of 213 companies for Return-on-Tangible-Asset. This places Pangaea Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pangaea Oncology and its competitors. Pangaea Oncology's current Return-on-Tangible-Asset is -24.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.10, compared to a current price of €1.55 — trading 26.2% below its estimated fair value. The current Return-on-Tangible-Asset is -24.22%. Pangaea Oncology's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Return-on-Tangible-Asset is -24.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 26.2% below its estimated GF Value™ of €2.10.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
Return-on-Tangible-Asset: -24.22%
GF Value™: €2.10 vs. price of €1.55 (26.2% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
65GF Score
Get the complete analysis for XMAD:PANG
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
